Foghorn Therapeutics Inc. (FHTX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $3.21M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $229.81M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $3.21M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $3.21M |
| Deferred revenue · latest quarter (USD) | $229.81M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $36.59M + $193.22M ≈ $229.81M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | $350.00K | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $350.00K − $0.00 ≈ $350.00K |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 284.43M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 3.21M USD | Accounts Payable, Current |
| Total deferred revenue | 229.81M USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | 36.59M USD | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | 193.22M USD | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | 350.00K USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability · Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- $350.00K
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $43.10M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.21M | $229.81M | (m) | $350.00K | $284.43M | (m) | $36.59M | $193.22M | $350.00K | $0.00 |
| 2026-03-31 | (m) | $3.32M | $245.89M | (m) | $453.00K | $298.57M | (m) | $52.30M | $193.59M | $453.00K | $0.00 |
| 2025-12-31 | (m) | $4.27M | $249.15M | (m) | $556.00K | $306.60M | (m) | $43.19M | $205.96M | $556.00K | $0.00 |
| 2025-09-30 | (m) | $3.21M | $258.40M | (m) | $656.00K | $294.62M | (m) | $65.30M | $193.10M | $656.00K | $0.00 |
| 2025-06-30 | (m) | $3.32M | $266.55M | (m) | $757.00K | $302.89M | (m) | $59.72M | $206.83M | $757.00K | $0.00 |
| 2025-03-31 | (m) | $4.07M | $274.11M | (m) | $856.00K | $320.34M | (m) | $51.67M | $222.44M | $856.00K | $0.00 |
| 2024-12-31 | (m) | $3.79M | $280.06M | (m) | (m) | $329.51M | (m) | $45.61M | $234.46M | (m) | $0.00 |
| 2024-09-30 | (m) | $3.45M | $282.92M | (m) | (m) | $336.66M | (m) | $33.38M | $249.53M | (m) | $0.00 |
| 2024-06-30 | (m) | $4.81M | $290.73M | (m) | (m) | $342.91M | (m) | $31.23M | $259.50M | (m) | $0.00 |
| 2024-03-31 | (m) | $5.63M | $297.62M | (m) | (m) | $352.49M | (m) | $31.50M | $266.11M | (m) | $0.00 |
| 2023-12-31 | (m) | $6.26M | $302.67M | (m) | $0.00 | $363.11M | (m) | $34.55M | $268.12M | $0.00 | $0.00 |
| 2023-09-30 | (m) | $6.50M | $308.43M | (m) | $0.00 | $370.81M | (m) | $28.34M | $280.09M | $0.00 | $0.00 |
| 2023-06-30 | (m) | $6.93M | $325.91M | (m) | $0.00 | $388.93M | (m) | $33.90M | $292.02M | $0.00 | $0.00 |
| 2023-03-31 | (m) | $7.29M | $331.51M | (m) | $0.00 | $397.47M | (m) | $33.33M | $298.18M | $0.00 | $0.00 |
| 2022-12-31 | (m) | $5.41M | $336.82M | (m) | $29.00K | $404.77M | (m) | $32.82M | $304.00M | $29.00K | $0.00 |
| 2022-09-30 | (m) | $5.26M | $341.00M | (m) | $58.00K | $409.61M | (m) | $33.16M | $307.84M | $58.00K | $0.00 |
| 2022-06-30 | (m) | $3.63M | $342.64M | (m) | $88.00K | $409.27M | (m) | $30.57M | $312.07M | $88.00K | $0.00 |
| 2022-03-31 | (m) | $5.07M | $347.13M | (m) | $116.00K | $415.90M | (m) | $30.06M | $317.07M | $116.00K | $0.00 |
| 2021-12-31 | (m) | $3.82M | $351.05M | (m) | $143.00K | $422.90M | (m) | $28.32M | $322.73M | $143.00K | $0.00 |
| 2021-09-30 | (m) | $3.82M | $15.00M | (m) | $171.00K | $105.09M | (m) | $1.28M | $12.69M | $171.00K | $0.00 |
| 2021-06-30 | (m) | $3.41M | $15.00M | (m) | (m) | $104.34M | (m) | $910.00K | $13.10M | (m) | $0.00 |
| 2021-03-31 | (m) | $2.91M | $15.00M | (m) | (m) | $104.72M | (m) | $2.41M | $11.88M | (m) | $0.00 |
| 2020-12-31 | (m) | $3.68M | $15.00M | (m) | (m) | $109.41M | (m) | $2.02M | $12.55M | (m) | $0.00 |
| 2020-09-30 | (m) | $3.55M | $15.00M | (m) | (m) | $99.35M | (m) | $1.70M | $13.13M | (m) | $0.00 |
| 2019-12-31 | (m) | $3.44M | (m) | (m) | (m) | $23.81M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |